Recent Phase 1b study results for its Crohn's disease treatment showed a favorable safety profile with no serious adverse events. :
According to data from WallStreetZen , several lower-priced biotechs show favorable Price-to-Earnings (P/E) ratios compared to industry peers as of early 2026: BioCryst Pharmaceuticals AUPH Aurinia Pharmaceuticals TBPH Theravance Biopharma PBYI Puma Biotechnology best biotech stocks to buy under $10
Currently receiving an from analysts at Wolfe Research , with a price target of $7. Recent Phase 1b study results for its Crohn's
: Highlighted for strengthening its global reach through strategic deals, such as the one with Kyowa Kirin. best biotech stocks to buy under $10
The primary catalyst is upcoming clinical data for ulcerative colitis, expected in the second half of 2027.